• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

FDA opens up generic competition

News
Article

FDA released new draft guidance designed to make it easier for generic manufacturers to introduce competition to 38 existing drug products, according to the agency’s Federal Register notice.

FDA released new draft guidance designed to make it easier for generic manufacturers to introduce competition to 38 existing drug products, according to the agency’s Federal Register notice.

“FDA adopted this process as a means to develop and disseminate product-specific BE [bioequivalent] recommendations and provide a meaningful opportunity for the public to consider and comment on those recommendations,” according to the notice.

Related: Specialty pharmaceuticals roundtable: Balancing benefits, cost

The bioequivalence recommendations apply to the Abbreviated New Drug Applicaton (ANDA) process and affect popular drugs such as avanafil (Stendra, Endo), lorcaserin HCl (Belviq, Eisai) and ticagrelor (Brilinta, AstraZeneca). FDA’s new draft guidance for industry on product-specific BE recommendations includes drug products containing the following active ingredients: avanafil, azilsartan kamedoxomil; chlorthalidone, buprenorphine HCl; naloxone HCl; chlorpheniramine maleate; ibuprofen; cyclosporine; deferiprone; desoximetasone; diclofenac; diphenhydramine HCl; naproxen sodium, loperamide HCl, minocycline HCl, oxybutynin chloride, potassium chloride and pyrimethamine.

Related: Biosimilar drugs could save US millions

Interested parties must submit either electronic or written comments on the draft by May 8, 2015.

The guidance stems back to FDA’s Federal Register notice of June 11, 2010, (75 FR 33311), when FDA announced the availability of a guidance for industry entitled “Bioequivalence Recommendations for Specific Products."

Read next: The rising cost of generic drugs

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.